IL7 and neoplasm: Humbach et al. showed that mesenchymal stem cells (MSCs) engineered to release IL-7/12 cytokines increase the anti-tumor activity of CAR T cells against colorectal carcinoma cells by altering the inflammatory action of Th2 to Th1/17 executive profile in the tumor milieu [104].